Bausch Health Companies Inc.
Health
Performance
6.6
Risk
Sell
Buy
Curious about the Scores? Learn more.

Bausch Health Companies Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

24.01.2026
Trouble brewing. Volatility and pressure rising.
16.01.2026
Breaking down. The red game over screen is flashing.
31.12.2025
Momentum tanked. Clearly underperforming.
20.08.2025
Pulse detected. Still fragile, but stabilizing.
BHC
Bausch Health Companies Inc.
6.16
+1.70%
6.6
Sell
Buy
Bausch Health Companies Inc.

Bausch Health Companies Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Bausch Health Companies Inc. do? Business model and key facts

Get the full picture of Bausch Health Companies Inc.: what it builds, where it operates, and how it makes money.

Bausch Health Companies Inc. Profile

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees (FY): 20700

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

shop
Company facts
Thomas J. Appio
CEO
20700
Employees worldwide
shop
Performance
-5.38%
Last 12 months
-79.52%
Last 5 years
shop
Growth
$9,52B
Revenue year
$-72.000.000
Net income
shop
Valuation
$2,28B
Market Cap
-67.73
Price/Earnings Ratio

Stocks related to Bausch Health Companies Inc.

Selected based on industry alignment and relative market positioning.

HCM
HUTCHMED (China) Limited
14.96
-1.91%
4.2
Sell
Buy
HUTCHMED (China) Limited
SUPN
Supernus Pharmaceuticals, Inc.
51.18
-0.68%
4.3
Sell
Buy
Supernus Pharmaceuticals, Inc.
INDV
Indivior Pharmaceuticals Inc
33.46
-1.46%
6.0
Sell
Buy
Indivior Pharmaceuticals Inc
AVDL
Avadel Pharmaceuticals plc
21.63
+0.05%
7.1
Sell
Buy
Avadel Pharmaceuticals plc
PAHC
Phibro Animal Health Corporation
51.74
-0.21%
4.1
Sell
Buy
Phibro Animal Health Corporation

Bausch Health Companies Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.